UCP2 and neoplasm: Importantly, the combined therapy of trastuzumab and UCP-2 inhibitor Genipin significantly suppressed tumor cell growth and promoted apoptosis in vitro, indicating that UCP-2 inhibition might be a novel therapeutic target to enhance anti-tumor efficacy of trastuzumab.